Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness study-Reference-Cited by-同舟云学术

Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness study

Published:2022-09 Issue:9 Volume:25 Page:
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:J Int AIDS Soc.

Author:

Garris Cindy P.¹,Czarnogorski Maggie¹,Dalessandro Marybeth²,D'Amico Ronald¹,Nwafor Toyin¹,Williams Will³,Merrill Deanna¹,Wang YuanYuan³,Stassek Larissa⁴,Wohlfeiler Michael B.⁵,Sinclair Gary I.⁶,Mena Leandro A.⁷,Thedinger Blair⁸,Flamm Jason A.⁹,Benson Paul¹⁰,Spreen William R.¹

Affiliation:

1. ViiV Healthcare Durham North Carolina USA

2. ViiV Healthcare Collegeville Pennsylvania USA

3. GlaxoSmithKline Collegeville Pennsylvania USA

4. Evidera Bethesda Maryland USA

5. AIDS Healthcare Foundation Los Angeles California USA

6. Prism Health North Texas Dallas Texas USA

7. University of Mississippi Medical Center Jackson Mississippi USA

8. KC CARE Health Center Kansas City Missouri USA

9. Kaiser Permanente Sacramento Sacramento California USA

10. Be Well Medical Center Berkley California USA

Funder

ViiV Healthcare

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jia2.26006

Reference15 articles.

1. Cabenuva [prescribing information].Research Triangle Park NC:ViiV Healthcare;2022.

2. Panel on Antiretroviral Guidelines for Adults and Adolescents [Internet]. [cited 2022 Jan 4]. Available from:https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf

3. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

4. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

5. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective;Molecular Pharmaceutics;2024-08-19

2. Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view;Journal of Antimicrobial Chemotherapy;2024-08-14

3. Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations;Journal of the International AIDS Society;2024-07

4. Long‐acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project;Journal of the International AIDS Society;2024-07

5. Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration;Open Forum Infectious Diseases;2024-05-25